We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Drug Compound to Treat 2 Life-Threatening Tropical Diseases
News

Novel Drug Compound to Treat 2 Life-Threatening Tropical Diseases

Novel Drug Compound to Treat 2 Life-Threatening Tropical Diseases
News

Novel Drug Compound to Treat 2 Life-Threatening Tropical Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novel Drug Compound to Treat 2 Life-Threatening Tropical Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Derived from nature, a potential new drug to treat two life-threatening tropical diseases has been discovered as a result of collaboration between two Welsh universities.

The team of researchers, led by Professor Andrew Westwell from Cardiff University, has successfully created a drug compound, from the goji berry plant, that is active against the parasites that cause schistosomiasis and fascioliasis.

Although not widely known, schistosomiasis is the most devastating human parasitic disease after malaria, with approximately 600 million people currently affected, and causing approximately 300,000 deaths per year. Likewise, 17 million people are currently infected with fascioliasis, with figures set to increase.

Schistosomiasis is caused by a waterborne parasite, while fascioliasis is caused by a foodborne parasite. Both of these neglected diseases are treated with a single drug, which is widely administered to the population where these diseases are most prevalent. However, this type of single treatment often leads to drug resistance, which is now the case for many people at risk of contracting these diseases.

As a result, a team of researchers at Cardiff University joined forces with Aberystwyth University's Institute of Biological, Environmental and Rural Sciences, led by Professor Karl Hoffmann, in a collaboration to find a new drug treatment.

Speaking of the research, Professor Westwell from Cardiff University's School of Pharmacy and Pharmaceutical Sciences, said: "Discovering a potential new treatment for two such prevalent diseases is an exciting find and we hope that this research will lead to major health benefits for some of the world's poorest people who are at risk of contracting Schistosomiasis and Fascioliasis."

Funded by the Welsh Government's Life Science Research Network of Wales, the drug design was carried out at Cardiff University's School of Pharmacy and Pharmaceutical Sciences and the testing of its effectiveness has taken place at Aberystwyth University.

The research 'Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues' is published in the European Journal of Medical Chemistry.

This article has been republished from materials provided by Cardiff University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement